对于淋巴结疾病有限的乳腺癌患者，不应进行腋窝清扫以确定阿贝西利的适用性。 - Suppr

Suppr

超能文献

Axillary dissection should not be performed in breast cancer patients with limited nodal disease to determine abemaciclib candidacy.

作者信息

Halsey Brenton, Fish Elizabeth McAuley, Lyons Walker, McShane Melissa, Williams Austin D

机构信息

Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

出版信息

Gland Surg. 2025 Jul 31;14(7):1183-1186. doi: 10.21037/gs-2025-178. Epub 2025 Jul 28.

DOI:10.21037/gs-2025-178

PMID:40771385

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12322772/

Abstract

摘要

相似文献

Axillary dissection should not be performed in breast cancer patients with limited nodal disease to determine abemaciclib candidacy.

Gland Surg. 2025 Jul 31;14(7):1183-1186. doi: 10.21037/gs-2025-178. Epub 2025 Jul 28.

Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.

Lancet Oncol. 2024 Sep;25(9):1222-1230. doi: 10.1016/S1470-2045(24)00350-4. Epub 2024 Aug 6.

Should abemaciclib candidacy be an indication for ALND?-commentary on SENOMAC post-hoc analysis.

Gland Surg. 2025 Apr 30;14(4):776-780. doi: 10.21037/gs-2025-38. Epub 2025 Apr 25.

Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis.

ESMO Open. 2025 Jun;10(6):105304. doi: 10.1016/j.esmoop.2025.105304. Epub 2025 Jun 13.

Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors.

Clin Breast Cancer. 2025 Feb;25(2):e159-e169.e2. doi: 10.1016/j.clbc.2024.08.022. Epub 2024 Aug 29.

Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.

Eur J Cancer. 2024 Sep;209:114239. doi: 10.1016/j.ejca.2024.114239. Epub 2024 Jul 21.

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.

J Clin Oncol. 2025 Mar 20;43(9):1101-1112. doi: 10.1200/JCO-24-02086. Epub 2024 Dec 18.

Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?

Cancer. 2024 Apr 1;130(7):1052-1060. doi: 10.1002/cncr.35136. Epub 2023 Nov 29.

Clinician's guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer.

Ther Adv Med Oncol. 2025 Mar 20;17:17588359251326710. doi: 10.1177/17588359251326710. eCollection 2025.

Role of abemaciclib in primary breast cancer: a narrative review of MonarchE.

Transl Breast Cancer Res. 2022 Jan 31;3:3. doi: 10.21037/tbcr-21-27. eCollection 2022.

本文引用的文献

Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor.

J Clin Oncol. 2025 Aug;43(22):2456-2460. doi: 10.1200/JCO-24-02683. Epub 2025 Apr 14.

Abemaciclib Therapy Using the MonarchE Criteria Results in Large Numbers of Excess Axillary Node Clearances-Time to Pause and Reflect?

Cancers (Basel). 2024 Sep 4;16(17):3072. doi: 10.3390/cancers16173072.

Lancet Oncol. 2024 Sep;25(9):1222-1230. doi: 10.1016/S1470-2045(24)00350-4. Epub 2024 Aug 6.

Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.

N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487.

Quality of Life After Axillary Lymph Node Dissection Among Racial and Ethnic Minority Women.

JAMA Surg. 2024 Jun 1;159(6):668-676. doi: 10.1001/jamasurg.2024.0118.

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

N Engl J Med. 2024 Mar 21;390(12):1080-1091. doi: 10.1056/NEJMoa2305488.

Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib.

Br J Cancer. 2024 Apr;130(7):1141-1148. doi: 10.1038/s41416-024-02580-3. Epub 2024 Jan 27.

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.

J Clin Oncol. 2024 Mar 20;42(9):987-993. doi: 10.1200/JCO.23.01994. Epub 2024 Jan 9.

Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?

Cancer. 2024 Apr 1;130(7):1052-1060. doi: 10.1002/cncr.35136. Epub 2023 Nov 29.

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验